Filing Details
- Accession Number:
- 0001171520-22-000426
- Form Type:
- 13D Filing
- Publication Date:
- 2022-07-21 20:00:00
- Filed By:
- Singer Julian D.
- Company:
- Gyre Therapeutics Inc. (NASDAQ:GYRE)
- Filing Date:
- 2022-07-22
- SEC Url:
- 13D Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| JDS1 | 0 | 2,247,442 | 0 | 2,247,442 | 2,247,442 | 7.1% |
| CCUR Holdings, Inc | 0 | 1,115,865 | 0 | 1,115,865 | 1,115,865 | 3.5% |
| CIDM II | 0 | 1,115,865 | 0 | 1,115,865 | 1,115,865 | 3.5 % |
| Julian D. Singer | 0 | 2,247,442 | 0 | 2,247,442 | 2,247,442 | 7.1% |
| David S. Oros | 388,600 | 0 | 388,600 | 0 | 388,600 | 1.2 % |
| Shelly C. Lombard | 0 | 0 | 0 | 0 | 0 | 0% |
| Matthew Stecker | 0 | 0 | 0 | 0 | 0 | 0% |
| Igor Volshteyn | 0 | 0 | 0 | 0 | 0 | 0% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(Amendment No. 15)1
| Catalyst Biosciences, Inc. | ||
| (Name of Issuer) | ||
| Common Stock, par value $0.001 per share | ||
| (Title of Class of Securities) | ||
| 14888D208 | ||
| (CUSIP Number) | ||
|
JULIAN D. SINGER | ||
| (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) | ||
| July 20, 2022 | ||
| (Date of Event which Requires Filing of this Statement) | ||
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box